The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). However, long-term follow-up data from drug-eluting stent trials are generally scarce. Silber et al. report the 2-year clinical outcomes from the original RESOLUTE […]
Tag: drug-eluting stents
DES show mortality benefit in AMI
Currently both bare metal stents (BMS) and drug-eluting stents (DES) are used during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). PCI has been demonstrated to reduce the rate of death or recurrent ischaemia when compared to medical therapy. To date trials comparing DES and BMS in acute MI have been limited by small […]